Unlabelled somatostatin analogues in treatment of digestive endocrine tumours

Reubi, 2001, Somatostatin receptors sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands, Eur. J. Nucl. Med., 28, 836, 10.1007/s002590100541 Kulaksiz, 2002, Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with subtype specific antibodies, Gut, 50, 52, 10.1136/gut.50.1.52 Macaulay, 1992, Insulin-like growth factors and cancer, Br. J. Cancer, 65, 311, 10.1038/bjc.1992.65 Sharma, 1998, Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells, Int. J. Cancer, 76, 259, 10.1002/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7 Garcia de la Torre, 2002, Antiangiogenic effects of somatostatin analogues, Clin. Endocrinol., 57, 425, 10.1046/j.1365-2265.2002.01619.x Kvols, 1986, Treatment of the malignant carcinoid syndrome: evaluation of long-acting somatostatin analogue, N. Engl. J. Med., 315, 663, 10.1056/NEJM198609113151102 Lamberts, 1996, Octreotide, N. Engl. J. Med., 334, 246, 10.1056/NEJM199601253340408 Eriksson, 1999, Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook, Ann. Oncol., 10, S31, 10.1023/A:1027352531144 Corleto, 2000, Long-term octreotide treatment of metastatic carcinoid tumor, Ann. Oncol., 11, 491, 10.1023/A:1008398431246 Angeletti, 1999, Single dose of octreotide stabilizes metastatic gastro-entero-pancreatic endocrine tumours, Ital. J. Gastroenterol. Hepatol., 31, 23 Gorden, 1989, Somatostatin and somatostatin analogue (SMS 201–995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non neoplastic disease of the gut, Ann. Intern. Med., 110, 35, 10.7326/0003-4819-110-1-35 Öberg, 1983, Effects of leukocyte interferon upon clinical symptoms and hormone levels in patients with midgut carcinoid tumors and the carcinoid syndrome, N. Engl. J. Med., 309, 129, 10.1056/NEJM198307213090301 Janson, 1992, Octreotide and interferon-α: a new combination for the treatment of malignant carcinoid tumors, Eur. J. Cancer, 28, 1647, 10.1016/0959-8049(92)90060-F Rubin, 1999, Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome, J. Clin. Oncol., 17, 600, 10.1200/JCO.1999.17.2.600 Wymenga, 1999, Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms, J. Clin. Oncol., 17, 1111, 10.1200/JCO.1999.17.4.1111 Anthony, 1999, Long-acting formulations of somatostatin analogues, Ital. J. Gastroenterol. Hepatol., 31, 216 Caron, 2002, Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly, J. Clin. Endocrinol. Metab., 87, 99, 10.1210/jc.87.1.99 Reubi, 2002, A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors, Eur. J. Pharmacol., 456, 45, 10.1016/S0014-2999(02)02651-1 Weckbecker, 2002, SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insuline-like growth factor-I axis in rats, primates, and dogs, Endocrinology, 143, 4123, 10.1210/en.2002-220219 Nagy, 1998, Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin, Proc. Natl. Acad. Sci. U.S.A., 95, 1794, 10.1073/pnas.95.4.1794 Ricci, 2000, Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide, Ann. Oncol., 11, 1127, 10.1023/A:1008383132024 Ricci, 2000, Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors, Am. J. Clin. Oncol., 23, 412, 10.1097/00000421-200008000-00020 Garland, 2003, Sandostatin LAR for malignant carcinoid syndrome: a 3-year experience, Aliment. Pharmacol. Ther., 17, 437, 10.1046/j.1365-2036.2003.01420.x O’Toole, 2000, Treatment of carcinoid syndrome. A prospective cross over evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance, Cancer, 88, 770, 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0 Ducreux, 2000, The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors, Am. J. Gastroenterol., 95, 3276, 10.1111/j.1572-0241.2000.03210.x Tomassetti, 2000, Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR, Aliment. Pharmacol. Ther., 14, 557, 10.1046/j.1365-2036.2000.00738.x Aparicio, 2001, Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours, Eur. J. Cancer, 37, 1014, 10.1016/S0959-8049(01)00073-9 Arnold, 1996, Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours, Gut, 38, 430, 10.1136/gut.38.3.430 Eriksson, 1997, High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects, Ann. Oncol., 8, 1041, 10.1023/A:1008205415035 Saltz, 1993, Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors, Cancer, 72, 244, 10.1002/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q Faiss, 1999, Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors, Digestion, 60, 469, 10.1159/000007693 Shojamanesh, 2002, Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma, Cancer, 94, 331, 10.1002/cncr.10195 Redfern, 1995, Octreotide-associated biliary tract dysfunction and gallstones formation: pathophysiology and management, Am. J. Gastroenterol., 90, 1042 Trendle, 1997, Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cells tumors, Cancer, 79, 830, 10.1002/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-# Eriksson B. Medical treatment of gastroenteropancreatic tumors with octreotide plus interferon. In: The expanding role of octreotide. I. Advances in oncology. Lamberts, Dogliotti (Bristol): BioScientifica; 2002. p. 103–12. Frank, 1999, Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors, Am. J. Gastroenterol., 94, 1381, 10.1016/S0002-9270(99)00146-X Fjallskog, 2002, Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs, Med. Oncol., 19, 35, 10.1385/MO:19:1:35 Szepeshazi, 2002, Targeted cytotoxic somatostatin analogue AN238 inhibits somatostatin receptor positive experimental colon cancers independently of their p53 status, Cancer Res., 62, 781 Plonowski, 2001, Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN238, Cancer, 92, 1168, 10.1002/1097-0142(20010901)92:5<1168::AID-CNCR1435>3.0.CO;2-6 Szepeshazi, 2001, Targeting of cytotoxic somatostatin analog AN238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancer, Clin. Cancer Res., 7, 2854 Benali, 2000, Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN238, Proc. Natl. Acad. Sci. U.S.A., 97, 9180, 10.1073/pnas.130196697 Koppan, 1998, Targeted cytotoxic analogue of somatostatin AN238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses, Cancer Res., 58, 4132